Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 347 (2) , 401-405
- https://doi.org/10.1016/j.bbrc.2006.06.037
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Marine natural products and their potential applications as anti-infective agentsThe Lancet Infectious Diseases, 2003
- In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeastsJournal of Antimicrobial Chemotherapy, 2003
- Antifungal Activity of Phenyllactic Acid against Molds Isolated from Bakery ProductsApplied and Environmental Microbiology, 2003
- Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000Journal of Clinical Microbiology, 2002
- Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough CandidemiaClinical Infectious Diseases, 2001
- Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care HospitalEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a reviewJournal of Antimicrobial Chemotherapy, 1999
- Azole resistance inCandidaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993